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Purpose
This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial
comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast
cancer.
Materials and Methods
A total of 77 patients were eligible for this study (38!in the TSU-68 plus docetaxel arm and
39 in the docetaxel alone arm). Blood samples were collected prior to the start of each
cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-
AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6)
levels were measured using enzyme linked immunosorbent assay. The primary endpoint
was progression-free survival (PFS). 
Results
In patients with baseline PDGF-AA " median, median PFS was significantly worse in the TSU-
68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months,
p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-
AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68
plus docetaxel group, PFS showed significant association with fold changes in CRP
(p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treat-
ment cycle. 
Conclusion
Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were pre-
dictive for the efficacy of TSU-68.
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Introduction
Angiogenesis is a fundamental event in breast cancer
growth and metastasis [1], and therefore has been a major
target in development of new agents for breast cancer. A
number of types of antiangiogenic agents have been investi-
gated in phase III trials in patients with advanced breast can-
cer [2]. Of these, oral small-molecule multikinase agents,
which inhibit diverse angiogenesis targets, including vascu-
lar endothelial growth factor receptor (VEGFR) and platelet-
derived growth factor receptor (PDGFR), have been widely
investigated, although their role in management of breast
cancer has yet to be established.
TSU-68 (orantinib), a novel oral antiangiogenic multikinase
agent, selectively inhibits VEGFR-2, PDGFR, and fibroblast
growth factor receptor (FGFR) [3]. Based on promising 
results from multiple single-arm phase II trials of TSU-68 in
patients with breast cancer [4,5], we previously conducted a
randomized phase II trial comparing the combination of
TSU-68 and docetaxel with docetaxel monotherapy in 
patients with metastatic breast cancer in whom anthracycline
therapy had failed [6].
In the era of targeted therapy, the role of biomarkers has
become increasingly important for selection of patients who
will benefit most, as the magnitude of benefit from each
agent varies among patients. A number of antiangiogenic
agents have been approved for management of various types
of cancers, although the role of biomarkers remains to be
clearly demonstrated for these agents. However, previous
studies have suggested the potential value of soluble plasma
proteins as pharmacodynamic and predictive biomarkers for
antiangiogenic agents [7]. Based on these findings, an 
exploratory translational study was incorporated into a ran-
domized phase II trial of TSU-68. Candidate markers related
to angiogenesis, apoptosis, and inflammation were analyzed
for the pharmacodynamics of TSU-68 and prediction of clin-
ical outcomes in breast cancer patients treated with TSU-68–
containing chemotherapy. Here, we report on the results of
this biomarker analysis of TSU-68 in patients with metastatic
breast cancer.
Materials and Methods
1. Patients, treatment, and outcome 
This study was an exploratory analysis of a multicenter
randomized phase II trial comparing TSU-68 plus docetaxel
with docetaxel alone in patients with metastatic breast cancer
who had previously received therapy with an anthracycline-
containing regimen. Eligible patients were randomized at a
1:1 ratio to receive either docetaxel 60 mg/m2 on day 1 plus
TSU-68 400 mg/m2 on days 1-21 every 3 weeks or docetaxel
60 mg/m2 alone on day 1 every 3 weeks. The primary end-
point was progression-free survival (PFS) by independent 
review. The details of this study have been published else-
where [6].
In brief, between November 2006 and December 2007, 77
patients were eligible for analysis (38!for TSU-68 plus doc-
etaxel and 39 for docetaxel alone). The median PFS was 6.8
months (95% confidence interval [CI], 5.4 to 12.5 months) in
the TSU-68 plus docetaxel group and 8.1 months (95% CI, 4.0
to 13.7 months) in the docetaxel-alone group (hazard ratio,
1.0; 95% CI, 0.6 to 1.8; p=0.95). No significant differences in
the overall response rates and overall survival were observed
between groups (p=0.29 and p=0.42, respectively). In sub-
group analyses for prespecified patient groups (anthracy-
cline sensitive/resistant, prior taxanes/non-prior taxanes,
estrogen receptor positive/negative, progesterone receptor
positive/negative, HER2 positive/negative, triple negative),
no differences in PFS was observed across all subgroups 
between arms. This study was approved by the institutional
review boards of each participating institution and con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. All participants provided
written informed consent before enrollment.
2. Plasma collection and enzyme-linked immunosorbent
assay assays
Blood samples were collected at baseline and prior to the
start of each cycle for evaluation of potential TSU-68 bio-
markers. Plasma levels of angiogenesis-related factors (vas-
cular endothelial growth factor [VEGF], platelet-derived
growth factor [PDGF]-AA, PDGF-AB, PDGF-BB, and fibrob-
last growth factor [FGF]), apoptosis markers (caspase-
cleaved fragment of cytokeratin 18 [M30]), and inflammatory
markers (C-reactive protein [CRP] and interleukin [IL]-6)
were measured using an enzyme-linked immunosorbent
assay according to the manufacturer’s instructions (R&D Sys-
tems, Minneapolis, MN).
The pharmacodynamics of TSU-68 was assessed by esti-
mation of fold changes in plasma biomarker concentration
from baseline to each cycle of the study treatment and their
maximal changes during the entire study course. For correl-
ative analysis of candidate plasma biomarkers, baseline
plasma concentration and fold changes from baseline to 
the end of the first cycle of the study treatment were dicho-
tomized according to the median values. In the patient sub-
group categorized by baseline biomarker levels, PFSs were
compared between the two arms to evaluate the impact of
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baseline biomarker levels on the benefit of TSU-68. Analysis
of fold changes in plasma biomarker concentrations from
baseline across study treatment cycles was performed to 
determine the relationship with PFS in each treatment arm.
3. Statistical analysis
The chi-square test or Fisher exact test was used to deter-
mine the association between categorical variables, as appro-
priate. Log-transformation of the plasma biomarker conce-
ntration was performed for comparison. Comparisons of the
means of biomarker-related variables between treatment
groups and within groups were performed using the Stu-
dent’s t test and Wilcoxon rank sum tests, respectively. The
Kaplan-Meier method was used for estimation of the proba-
bility of survival, with comparison using a log-rank test. PFS
was defined as the time between randomization and disease
progression or death from any cause, whichever occurred
first. Correlation analyses in terms of PFS were performed
using baseline biomarker levels, and fold changes after the
first cycle of study treatment. A p-value of < 0.05 was con-
sidered statistically significant, and all analyses were per-
formed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL).
Results
1. Baseline plasma biomarker levels
Blood samples at baseline were available for all patients
included in the phase II trial (38 for TSU-68 plus docetaxel
and 39 for docetaxel alone). There were no significant differ-
ences in the baseline characteristics between the two groups
(Table 1). The baseline levels of plasma biomarkers in the
TSU-68 plus docetaxel and docetaxel-alone groups are sum-
marized in Table 2. There were no significant differences in
Table 1. Baseline characteristics
Characteristic TSU-68+docetaxel (n=38) Docetaxel (n=39) p-value
Age, median(range, yr) 52 (25-68) 50 (30-73) 0.57
ECOG performance status
0 21 (55) 19 (49) 0.65
1-2 17 (45) 20 (51)
Menopausal status
Premenopausal 11 (29) 16 (41) 0.34
Postmenopausal 27 (71) 23 (59)
Anthracycline sensitivity
Resistant 13 (34) 12 (31) 0.81
Sensitive 25 (66) 27 (69)
HER2 status (IHC or FISH) 33 ( 39 ( 0.74
Positive 6 (16) 5 (13)
Negative 27 (71) 34 (87)
Estrogen receptor status 37 ( 39 ( 0.11
Positive 26 (70) 20 (51)
Negative 11 (30) 19 (49)
Progesterone receptor status 37 ( 39 ( 0.49
Positive 20 (54) 17 (44)
Negative 17 (46) 22 (56)
Previous therapy
Surgery 34 (90) 38 (97) 0.20
Hormonal therapy 25 (66) 23 (59) 0.64
Radiotherapy 21 (55) 26 (67) 0.35
Chemotherapy
Anthracycline 38 (100) 39 (100) > 0.99
Taxanes 8 (21) 8 (21) > 0.99
Values are presented as number (%). ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; FISH, flu-
orescence in situ hybridization.
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the baseline plasma concentrations of biomarkers between
the two treatment arms (Table 2, Fig. 1).
2. Plasma biomarker dynamics with study treatment
Maximal changes from baseline values were calculated for
each biomarker using all evaluated values during serial
measurements. Estimation and comparison of the ratios of
the geometric mean of maximal biomarker changes in the
TSU-68 plus docetaxel group to those in the docetaxel-alone
group was performed to assess the magnitude of maximal
changes in biomarkers according to the treatment arm 
(Fig. 2). However, no significant differences in the maximal
changes in plasma levels of all evaluated biomarkers were
observed between the two arms: CRP (ratio, 1,45; p=0.52),
FGF (0.97; p=0.89), IL-6 (0.88; p=0.80), M30 (0.80; p=0.34),
PDGF-AA (1.18; p=0.08), PDGF-AB (1.06; p=0.68), PDGF-BB
(0.73; p=0.11), and VEGF (0.87; p=0.34).
The fold changes after the first cycle of study treatment for
each biomarker are summarized in Table 2. In the TSU-68
plus docetaxel group, the levels of CRP (median fold change,
1.5; p=0.002), PDGF-AA (1.3; p < 0.001), PDGF-AB (1.1;
p=0.003), and VEGF (1.1; p=0.001) were significantly incre-
ased at the end of the first cycle compared to those at base-
line. In the docetaxel-alone group, there was a significant
increase only in VEGF level (1.2; p=0.002).  
3. Baseline plasma biomarkers as a predictive factor
In each subgroup categorized by the baseline biomarker
levels (< median vs. " median), PFS was compared between
the TSU-68 plus docetaxel group and the docetaxel-alone
group. In patients with low baseline PDGF-AA levels, 
patients treated with TSU-68 plus docetaxel had significantly
worse median PFS than those treated with docetaxel alone
(5.4 months [95% CI, 2.1 to 8.6 months] vs. 13.7 months [95%
CI, 5.5 to 21.9 months]; p=0.049), whereas a trend toward a
benefit on PFS was observed in the TSU-68 plus docetaxel
group compared with the docetaxel-alone group in patients
with high baseline PDGF-AA levels (9.7 months [95% CI, 4.2
to 15.2 months] vs. 4.0 months [95% CI, 0.0 to 8.3 months];
p=0.18) (Fig. 3). There was a significant interaction between
the PFS benefit of TSU-68 and baseline PDGF-AA levels
(p=0.03). Otherwise, no difference in PFS was observed 
between the two arms for all other comparisons in subgroups
categorized by the baseline levels of all other candidate bio-
markers (p > 0.1).
4. Correlation between biomarker dynamics and PFS
The association between the dynamics of plasma biomark-
ers and PFS was assessed in each treatment arm. For each
biomarker, patients were grouped based on the median fold
change from baseline to the end of the first cycle of the study
treatment (< median vs. " median). In patients treated with
the combination of TSU-68 and docetaxel, PFS showed sig-
nificant association with fold changes in CRP (p=0.001), IL-6
(p < 0.001), PDGF-BB (p=0.02), and VEGF (p=0.047) follow-
ing the first treatment cycle (Fig. 4). For all of these four bio-
markers, patients with high fold changes had a better median
PFS than those with low fold changes: CRP (15.8 months
[95% CI, 8.4 to 23.2 months] vs. 5.4 months [95% CI, 1.1 to 9.6
months]), IL-6 (18.9 months [95% CI, 2.3 to 35.6 months] vs.
4.8 months [95% CI, 1.5 to 8.1 months]), PDGF-BB (12.5
months [95% CI, 6.0 to 19.0 months] vs. 5.4 months [95% CI,
3.7 to 7.1 months]), and VEGF (15.8 months [95% CI, 3.2 to
28.4 months] vs. 5.4 months [95% CI, 3.8 to 6.9 months]). In
patients included in the docetaxel-alone arm, however, PFS
was not related to the dynamics of all tested biomarkers after
the first cycle: CRP (p=0.41), FGF (p=0.99), IL-6 (p=0.16), M30
(p=0.30), PDGF-AA (p=0.73), PDGF-AB (p=0.95), PDGF-BB
(p=0.36), and VEGF (p=0.80).
Discussion
In our current study, we found that the activity of TSU-68,
which inhibits VEGFR-2, PDGFR, and FGFR, might be 
affected by baseline plasma PDGF-AA levels. The dynamics
of circulating soluble proteins that reflect angiogenesis and
tumor microenvironmental status showed correlation with
PFS in patients treated with TSU-68, but not in those who 
received cytotoxic chemotherapy alone. Our findings have
implications for the clinical development of TSU-68 and the
identification of potential biomarkers for TSU-68.
The combination of TSU-68 and docetaxel induced signif-
icant increases in the levels of CRP, PDGF-AA, PDGF-AB,
and VEGF at the end of the first cycle compared to those at
baseline, while VEGF was the only marker showing a signif-
icant increase with docetaxel. However, in comparison of the
maximal magnitude of changes in biomarkers during the 
serial measurements, no significant difference in any bio-
marker was observed between the two groups. Previous
studies have reported conflicting results regarding the phar-
macodynamic effects of TSU-68 [4,5,8]. In several studies, no
significant changes in angiogenesis-related plasma proteins
were observed after treatment with TSU-68 [4,5]. Although
a previous pharmacodynamic analysis of colorectal cancer
patients treated with TSU-68 in combination with fluoropy-
rimidine and oxaliplatin reported a significant decrease in
the PDGF series (PDGF-AA, AB, and BB) [8], it is unlikely
that this result reflects the pharmacodynamic features of
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Table 2. Levels of biomarkers at baseline and their fold changes after cycle 1 of study treatment
Baseline level Fold change after cycle 1
Characteristic Docetaxel, TSU-68+docetaxel, p-value Docetaxel, p-valuea) TSU-68+docetaxel, p-valuea)mean±SD mean±SD median (IQR) median (IQR)
CRP (mg/dL) 1.36±2.59 1.09±2.32 0.29 1.2 (0.3-4.9) 0.1 1.5 (0.7-6.8) 0.002
FGF (pg/mL) 6.53±3.97 6.53±3.99 0.95 1.0 (0.9-1.3) 0.33 1.0 (0.9-1.3) 0.52
IL-6 (pg/mL) 7.82±13.72 3.63±4.29 0.30 0.6 (0.3-1.2) 0.23 0.7 (0.3-1.5) 0.52
M30 (U/L) 366.89±614.59 486.49±1,366.17 0.88 0.9 (0.7-1.2) 0.22 0.9 (0.5-1.1) 0.09
PDGF-AA (pg/mL) 3,287.00±1,327.31 3,577.89±1,574.69 0.43 1.1 (0.9-1.3) 0.09 1.3 (1.0-1.4) < 0.001
PDGF-AB (pg/mL) 24,534.03±10,548.00 25,764.36±9,447.64 0.49 1.0 (0.9-1.2) 0.99 1.1 (0.9-1.4) 0.003
PDGF-BB (pg/mL) 2,799.00±1,463.33 2,567.10±1,640.16 0.31 1.0 (0.8-1.3) 0.84 1.1 (0.8-1.3) 0.28
VEGF (pg/mL) 435.86±361.51 388.27±238.25 0.81 1.2 (0.9-1.4) 0.002 1.1 (1.0-1.5) 0.001
SD, standard deviation; IQR, interquartile range; CRP, C-reactive protein; FGF, fibroblast growth factor; IL, interleukin;
PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor. a)Difference between the levels at baseline
and after cycle 1 within the study group.
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Fig. 1. Baseline levels of candidate plasma biomarkers between treatment arms. CRP, C-reactive protein; FGF, fibroblast
growth factor; IL, interleukin; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; DTX, doc-
etaxel.
TSU-68 itself. Although it is possible that docetaxel con-
founded the effect of TSU-68 in our study, due to the ran-
domized design of this trial, we were able to evaluate the
pharmacodynamic impact of the addition of TSU-68 to doc-
etaxel monotherapy. The limited impact of TSU-68 on phar-
macodynamic markers in many trials, including ours,
suggests that the current dose and schedule for TSU-68 may
not be optimal to induce significant target inhibition and clin-
ical efficacy.
In our primary analysis of this randomized phase II trial,
TSU-68 plus docetaxel did not demonstrate superiority to 
docetaxel alone in terms of PFS [6]. In addition, when 
patients were categorized by clinical factors, including hor-
mone receptors, HER-2 overexpression, and resistance to
previous therapy, there was no subgroup benefit from com-
bination therapy.
In our subanalysis of biomarker for TSU-68, we found that
the efficacy of TSU-68 may depend on the pretreatment
plasma concentration of PDGF-AA. The addition of TSU-68
appears to be associated with improved PFS in patients with
low baseline PDGF-AA levels. However, a detrimental effect
of TSU-68 was observed in patients with high baseline
PDGF-AA levels, which contrasts with the expectation that
PDGFR inhibition by TSU-68 may be more effective in 
patients with PDGF overexpression. This finding seems to
be in line with the results of a previous randomized phase II
study that compared TSU-68 with observation in patients
with hepatocellular carcinoma [9]. Although the result was
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Fig. 2. Maximal fold changes in candidate plasma biomarkers during the entire study course between treatment arms.
Ratio=(Geometric mean of maximal fold changes in the TSU-68 plus docetaxel group)/(Geometric mean of maximal fold
changes in the docetaxel-alone group). CRP, C-reactive protein; FGF, fibroblast growth factor; IL, interleukin; PDGF, platelet-
derived growth factor; VEGF, vascular endothelial growth factor; DTX, docetaxel.
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not statistically significant, patients who received TSU-68
had a numerically longer PFS than those included in the 
observation arm in the subgroup with low baseline PDGF-
AA levels, whereas this trend was reversed in patients with
high baseline PDGF-AA levels.
Until recently, investigation of the predictive role of circu-
lating dimeric PDGF isoforms for antiangiogenic agents has
been limited. Dimeric PDGF isoforms primarily induce
paracrine stimulation of stromal fibroblasts and perivascular
cells and also activate autocrine signaling for the prolifera-
tion of tumors [10]. However, the mechanism of the interac-
tion between PDGF-AA and TSU-68 efficacy is unclear and
will have to be defined in future studies. In many clinical tri-
als for unselected patients with various types of cancer, TSU-
68 has not demonstrated a significant improvement in clin-
ical outcomes [6,9,11]. Although the implication of PDGF-
AA as a predictive factor for TSU-68 should be validated in
a large patient population, our results indicate that further
investigations of TSU-68 for patients with relatively low 
expression of PDGF-AA will be necessary.
Monitoring of the dynamics of circulating protein bio-
markers may provide the opportunity to predict clinical out-
comes as well as achieve a better understanding of the
mechanism of action of investigational drugs. In our current
study, the dynamics of CRP, IL-6, PDGF-BB, and VEGF lev-
els showed significant association with PFS in patients
treated with TSU-68 plus docetaxel. This result confirms that
the activity of TSU-68 is driven by the inhibition of angio-
genesis and by its impact on the tumor microenvironment.
The relationship between the dynamics of plasma biomark-
ers and PFS was not seen in patients who received docetaxel
monotherapy, thus the significance of our finding appears
quite robust. A greater increase above the median in plasma
VEGF (a median fold increase of 1.1) and PDGF-BB (1.1) fol-
lowing TSU-68 plus docetaxel was associated with better
PFS. Given that inhibition of VEGFR and PDGFR results in a
reactive increase in plasma VEGF and PDGF-BB [4,12], this
result may indicate that stronger VEGFR and PDGFR inhi-
bition leads to a better PFS with TSU-68 treatment. 
IL-6 is a proinflammatory marker and CRP is a well-
known indicator of inflammatory status [13,14]. Patients with
fold changes above the median in CRP (the median of 1.5)
and IL-6 (0.7) after treatment with TSU-68 had improved
clinical outcomes in terms of PFS compared with those who
showed less increased or decreased CRP and greater decr-
ease of IL-6, respectively. Increases in these inflammatory
markers can be regarded as a consequence of therapy-
induced inflammation [13]. Death of cancer cells from anti-
cancer treatment induces the release of necrotic products,
leading to stimulation of cytokine-producing inflammatory
cells. Currently, it is unclear whether therapy-induced infl-
ammation is beneficial or harmful in cancer treatment [13].
The inflammation may stimulate residual cancer cells and
help in regrowth via the activation of prosurvival genes;
however, inflammation may also lead to activation of adap-
tive anti-tumor immune responses due to the increased pres-
entation of tumor antigens. Further investigations will be
needed in order to elucidate the effects of the dynamics of
these biomarkers, which reflect the status of the tumor 
microenvironment, on the efficacy of antiangiogenic agents.
There are several limitations to our current study. Altho-
ugh the randomized design of this trial enabled comparisons
of the impact of candidate biomarkers for TSU-68, our analy-
sis was based on a small number of patients, limiting the abil-
ity of the multivariate analysis to adjust for potential
confounding effects.
Conclusion
Results of our current exploratory analysis suggested that
the baseline plasma concentration of PDGF-AA might be pre-
dictive of the efficacy of antiangiogenic agents, including
TSU-68. As the addition of TSU-68 was detrimental in 
patients with high baseline PDGF-AA levels, this association
should be validated in future studies and considered in the
design of trials for the clinical development of TSU-68. A sig-
nificant relationship between PFS with TSU-68 treatment and
the dynamics of VEGF, PDGF-BB, CRP, and IL-6 confirmed
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that the efficacy of TSU-68 is due in part to the inhibition of
angiogenesis/lymphangiogenesis as well as the inflamma-
tory reaction, and also suggested that interim monitoring of
these markers may be useful for prediction of outcomes.
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